Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed supratentorial glioblastoma multiforme or gliosarcoma
• Completed standard external beam radiotherapy within the past 5 weeks
• Stable disease by MRI or CT scan
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 60-100%
• Life expectancy
• More than 4 months
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• No history of bleeding disorder
• Hepatic
• Bilirubin less than 1.5 mg/dL
• SGPT less than 2.5 times normal
• Alkaline phosphatase less than 2.5 times normal
• Renal
• BUN less than 1.5 times upper limit of normal (ULN) OR
• Creatinine less than 1.5 times ULN
• Cardiovascular
• No deep vein thrombosis within the past 3 weeks (must be clinically stable)
• Pulmonary
• No pulmonary embolism within the past 3 weeks (must be clinically stable)
• Other
• Must participate in System for Thalidomide Education and Prescribing Safety program
• No peripheral neuropathy grade 2 or greater
• No active infection
• No concurrent illness that may obscure toxicity or dangerously alter drug metabolism
• No other serious concurrent illness
• No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use 2 forms of effective contraception for 1 month before, during, and for 1 month after study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior thalidomide
• No concurrent immunotherapy
• No concurrent prophylactic filgrastim (G-CSF)
• Chemotherapy
• No prior chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent hormonal therapy
• Concurrent corticosteroids must be at stable or decreasing dose over the past 7 days
• Radiotherapy
• See Disease Characteristics
• No concurrent radiotherapy
• Surgery
• No concurrent surgery
• Other
• No other concurrent anticancer therapy
• No other concurrent investigational agents